Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

• Main Authors: Eltahir A G Khalil (Author), Teklu Weldegebreal (Author), Brima M Younis (Author), Raymond Omollo (Author), Ahmed M Musa (Author), Workagegnehu Hailu (Author), Abuzaid A Abuzaid (Author), Thomas P C Dorlo (Author), Zewdu Hurissa (Author), Sisay Yifru (Author), William Haleke (Author), Peter G Smith (Author), Sally Ellis (Author), Manica Balasegaram (Author), Ahmed M EL-Hassan (Author), Gerard J Schoone (Author), Monique Wasunna (Author), Robert Kimutai (Author), Tansy Edwards (Author), Asrat Hailu (Author)
• Formato: Livro
• Publicado em: Public Library of Science (PLoS), 2014-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Anti-leishmanial drug regimens that include a single dose AmBisome could be suitable for eastern African patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown.A multi-centre, open-label, non-inferiority, randomized controlled trial with an adaptive design,...